Clinical and Translational Oncology (CLIN TRANSL ONCOL)

Publisher: Federación de Sociedades Españolas de Oncología; Instituto Nacional de Cancerología de México, Springer Verlag

Journal description

Clinical and Translational Oncology is an international journal devoted to fostering interaction between experimental and clinical oncology. It covers all aspects of research on cancer, from the more basic discoveries dealing with both cell and molecular biology of tumour cells, to the most advanced clinical assays of conventional and new drugs. In addition, the journal has a strong commitment to facilitating the transfer of knowledge from the basic laboratory to the clinical practice, with the publication of educational series devoted to closing the gap between molecular and clinical oncologists. Molecular biology of tumours, identification of new targets for cancer therapy, and new technologies for research and treatment of cancer are the major themes covered by the educational series. Full research articles on a broad spectrum of subjects, including the molecular and cellular bases of disease, aetiology, pathophysiology, pathology, epidemiology, clinical features, and the diagnosis, prognosis and treatment of cancer, will be considered for publication. Case reports describing unusual clinical cases or examples of unique reports dedicated to translational research will also be within the scope of the journal.

Current impact factor: 2.08

Impact Factor Rankings

2015 Impact Factor Available summer 2016
2014 Impact Factor 2.077
2013 Impact Factor 1.6
2012 Impact Factor 1.276
2011 Impact Factor 1.327
2010 Impact Factor 1.254
2009 Impact Factor 1.146

Impact factor over time

Impact factor

Additional details

5-year impact 1.60
Cited half-life 3.60
Immediacy index 0.46
Eigenfactor 0.00
Article influence 0.41
Website Clinical and Translational Oncology website
Other titles Clinical & translational oncology (Online), Clinical and translational oncology
ISSN 1699-048X
OCLC 163567079
Material type Document, Periodical, Internet resource
Document type Internet Resource, Computer File, Journal / Magazine / Newspaper

Publisher details

Springer Verlag

  • Pre-print
    • Author can archive a pre-print version
  • Post-print
    • Author can archive a post-print version
  • Conditions
    • Author's pre-print on pre-print servers such as
    • Author's post-print on author's personal website immediately
    • Author's post-print on any open access repository after 12 months after publication
    • Publisher's version/PDF cannot be used
    • Published source must be acknowledged
    • Must link to publisher version
    • Set phrase to accompany link to published version (see policy)
    • Articles in some journals can be made Open Access on payment of additional charge
  • Classification
    ​ green

Publications in this journal

  • Clinical and Translational Oncology 09/2015; DOI:10.1007/s12094-015-1404-x
  • [Show abstract] [Hide abstract]
    ABSTRACT: Limited data exist regarding the safety and efficacy of bevacizumab in pediatric patients under the age of 4 years. Here, we report a large cohort of pediatric patients under 4 years of age treated with bevacizumab. The primary objective was to document adverse events with a possible relationship to bevacizumab. Patients (n = 16) were identified through retrospective chart review and harbored a variety of conditions (44 % central nervous system (CNS) tumors, 31 % vascular anomalies, 13 % neuroblastoma, 12 % other). The median age was 34.3 months (range 4.9-47.3), including five patients <2 years of age. Patients received bevacizumab for a median duration of 6.2 months, alone or with chemotherapy, and a median dose of 9.25 mg/kg (range 7.0-11.8). Partial responses were seen in 19 % of patients, and clinical improvements were seen in 69 %. Adverse events known to be associated with bevacizumab occurred in 37 %. Outcomes observed in this population resemble those reported for bevacizumab in older pediatric patients. The overall pattern and frequency of adverse events observed was similar to those seen in reports of older pediatric patients with a variety of conditions. The highest level of efficacy observed was seen among patients with vascular malformations or with low-grade CNS tumors. Our results suggest that the use of bevacizumab is safe for the youngest children.
    Clinical and Translational Oncology 08/2015; DOI:10.1007/s12094-015-1389-5
  • [Show abstract] [Hide abstract]
    ABSTRACT: To analyse the prognostic role of the immunohistochemical expression of pKDR in patients with advanced colorectal cancer treated with oxaliplatin and fluoropyrimidines combination chemotherapy with or without bevacizumab. Retrospective multicentre study, carried out at four hospitals in the Valencian Community (Spain). Patients evolution was compared based on the immunohistochemical expression of pKDR, classified using 4 categories: 0 (undetectable), 1 (mild), 2 (moderate) and 3 (high intensity). Patients were divided into two groups for the analysis: group 1 with low expression (0-1) vs. group 2 with high expression (2-3). Histological samples for the pKDR analysis were available for 84 of the 112 patients selected. Seven (8.3 %) had undetectable or mild expression of pKDR (Group 1) and 77 (91.7 %) showed moderate or high expression of pKDR (Group 2). Response rate in Group 1 was 100 % compared to 54.2 % in Group 2 (p = 0.019). Progression-free survival (PFS) (15 vs. 12 months, p = 0.4) and overall survival (OS) (28 vs. 22 months, p = 0.09) were numerically but not significantly higher in patients from Group 1 vs. Group 2. Patients from Group 2 who received bevacizumab presented a significantly higher PFS (13 vs. 11, p = 0.015) and a numerically higher OS (23 vs. 17 months, p = 0.27) than those treated exclusively with chemotherapy. Our results suggest that the absence or low expression of pKDR is associated with a better prognostic profile in patients with advanced colorectal cancer treated with chemotherapy and bevacizumab. Patients with a high pKDR expression benefit from the combination of chemotherapy with bevacizumab.
    Clinical and Translational Oncology 08/2015; DOI:10.1007/s12094-015-1378-8
  • [Show abstract] [Hide abstract]
    ABSTRACT: Although miR-203 has been proposed as a relevant biomarker for several cancers, the validated prognostic significance of miR-203 in lung cancer remains obscure. Thus, we aimed to identify the relationship between miR-203 expression and clinicopathological significance in non-small cell lung cancer (NSCLC) patients in the current study. The expression of miR-203 in 125 cases of NSCLC and their paired adjacent non-cancerous tissues was evaluated by quantitative reverse transcription polymerase chain reaction (qRT-PCR). Simultaneously, the correlation of miR-203 expression with a variety of clinicopathological factors and patient survival was analyzed. Functionally, in vitro effects of miR-203 on proliferation and viability were explored in lung cancer H460, A549, H1299, PC9 and H292 cells, as assessed by MTS tetrazolium assay and fluorimetric resorufin viability assay, respectively. The relative level of miR-203 was 6.12 ± 6.25 in NSCLC tissues, remarkably downregulated than that of their paired non-tumorous lung tissues (7.88 ± 5.56, P = 0.019). The area under curve (AUC) of low expression of miR-203 to diagnose NSCLC was 0.622 (95 % CI 0.552-0.692, P = 0.001). MiR-203 expression was negatively correlated to lymphatic metastasis (r = -0.334, P < 0.001), tumor size (r = -0.407, P < 0.001) and clinical TNM stages (r = -0.298, P = 0.001). Furthermore, the survival of the low miR-203 expression group was 4.88 ± 4.38 months, markedly shorter than that of the high expression group (23.35 ± 1.12 months, P < 0.001). The level of miR-203 was an independent prognostic indicator of NSCLC using univariate analysis. MiR-203 mimic could suppress the cell growth of five lung cancer cell lines tested to different degrees in vitro. MiR-203 could become a prognostic predictor in NSCLC and may be a new target for the molecular therapy of NSCLC patients.
    Clinical and Translational Oncology 08/2015; DOI:10.1007/s12094-015-1377-9
  • [Show abstract] [Hide abstract]
    ABSTRACT: INTRODUCTION: Nectins are a family of integral protein and immunoglobulin-like cell adhesion molecules involved in the formation of functioning adherence and tight junctions. Aberrant expression is associated with cancer progression, apoptosis and cell proliferation but little is known how these effects change in cell behavior. The objective of this study was to evaluate the serum levels of nectin-2 with regard to diagnostic, predictive and prognostic value in colorectal cancer (CRC) patients. MATERIALS AND METHODS: One-hundred and forty CRC patients were enrolled in this study. Serum nectin-2 levels were determined by enzyme-linked immunosorbent assay method. Age- and sex-matched 40 healthy controls were included in the analysis. RESULTS: Median age of patients was 60 years old, range 24-84 years. The localization of tumor in majority of the patients was colon (n = 81, 58 %). Non-metastatic (stage II and III) and metastatic patients' baseline serum nectin-2 levels were significantly higher than those in the healthy control group (p < 0.001; for two group). However, known clinical variables including response to CTx (chemotherapy) were not found to be correlated with serum nectin-2 concentrations (p > 0.05). While non-metastatic group patients with elevated serum nectin-2 levels showed significant adverse effect on PFS, metastatic group patients with elevated serum nectin-2 levels showed no significant adverse effect on PFS (p = 0.05 and p = 0.29, respectively). On the other hand, our study results did not show statistically significant serum nectin-2 concentrations regarding overall survival rates. CONCLUSION: Serum levels of nectin-2 may have diagnostic roles for CRC patients. Moreover, our study results show the prognostic role of nectin-2 in non-metastatic group patients.
    Clinical and Translational Oncology 07/2015; DOI:10.1007/s12094-015-1348-1
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose Genetic factors play an important role in our predisposition to cancer. Genome-wide association studies have linked the chromosome 15q25.1 locus to lung cancer susceptibility and implicated proteasome subunit alpha type-4 (PSMA4) as a candidate gene. In this case–control study, pathologically confirmed lung cancer patients and controls from the Chinese Han population were investigated to determine the effect of variant genotypes within the PSMA4 locus on susceptibility to lung cancer and sensitivity to cisplatin-based chemotherapy. Methods We identified validated tagged single nucleotide polymorphisms (tSNPs) with minor allele frequency >5 % in the HapMap Chinese Han Beijing population and genotyped seven SNPs within the PSMA4 locus. Their correlation with lung cancer risks and treatment response were examined using χ 2 test and haplotype analysis. Multivariate logistic regression analysis tested the association between the polymorphisms and chemotherapy response. Results rs12901682 is associated with lung cancer risks (OR = 1.45, 95 % CI, 1.04–2.02; P = 0.029). Using SNPStats software, we found rs12901682 (OR = 6.30, 95 % CI, 1.31–30.26; P = 0.0073) associated with lung cancer risks in the recessive model. Haplotype analysis showed that “CAGAATC” conferred an increased risk of lung cancer (OR = 1.50, 95 % CI, 1.07–2.11; P = 0.019). After adjustment for age, this association was pronounced in the male gender (OR = 6.30, 95 % CI, 1.31–30.26; P = 0.0073). PSMA4 polymorphisms did not affect the tumor sensitivity to cisplatin combination chemotherapy. Conclusions Our study suggests a potential association between PSMA4 variants and lung cancer risk in Chinese Han population.
    Clinical and Translational Oncology 07/2015; 17(7):564-569. DOI:10.1007/s12094-015-1279-x.
  • [Show abstract] [Hide abstract]
    ABSTRACT: In the last few years, many prospective studies have demonstrated a clear association between obesity and cancers of the colon and rectum, breast in post-menopausal women, endometrium, kidney, oesophagus and pancreas. Obesity is also associated with a high risk of recurrence and cancer-related death. The pathophysiology of obesity involves various changes that may be implicated in the relationship between obesity and cancer, such as excess inflammatory cytokines and chronic inflammation, hyperinsulinaemia, insulin resistance, and raised leptin and oestrogens. The Spanish Society for the Study of Obesity and the Spanish Society of Medical Oncology have signed a cooperation agreement to work together towards reducing the impact of obesity in cancer. Preventing obesity prevents cancer.
    Clinical and Translational Oncology 06/2015; DOI:10.1007/s12094-015-1306-y
  • [Show abstract] [Hide abstract]
    ABSTRACT: This study is to evaluate the association of polymorphisms of glutathione S-transferase P1 (GSTP1), copper-transporting P-type adenosine triphosphatase A (ATP7A) and X-ray repair cross-complementing group 1 (XRCC1) with the efficacy and toxicity of cisplatin-based treatment in advanced non-small cell lung cancer (NSCLC) patients. The outcomes of 97 advanced non-small cell lung cancer patients treated with cisplatin-based chemotherapy were estimated. GSTP1, ATP7A, and XRCC1 genetic polymorphisms were determined via polymerase chain reaction of restriction fragment length polymorphism (PCR-RFLP) and DNA sequencing. Association of the polymorphisms with the efficacy and toxicity of cisplatin was analyzed, respectively. Significant associations were observed between GSTP1 A313G and response rate (RR) (p = 0.027), disease control rate (DCR) (p = 0.019), and progression-free survival (PFS) (p = 0.044), respectively. Patients with AG and GG of GSTP1 have notably lower risk of anemia (p = 0.046). XRCC1 A1196G was associated with the incidence of lymphopenia (p = 0.024) and diarrhea (p = 0.020). ATP7A C2299G was not related with RR, DCR, PFS, and the risk of toxicity. Advanced NSCLC patients with AA genotype of GSTP1 would obtain better curative effect followed with more risk of anemia when treated by cisplatin-based chemotherapy. ATP7A C2299G does not impact the efficacy and toxicity of cisplatin-based chemotherapy. XRCC1 1196A allele could predict the incidence of lymphopenia and diarrhea.
    Clinical and Translational Oncology 06/2015; 17(9). DOI:10.1007/s12094-015-1299-6
  • [Show abstract] [Hide abstract]
    ABSTRACT: The aim of this prospective and multicentric phase II study was to evaluate the efficacy and safety of temozolomide (TMZ) and bevacizumab (BV) in patients (pts) with recurrent glioblastoma (GB), previously treated with chemoradiotherapy and at least three cycles of adjuvant TMZ. Patients with GB at first relapse received BV 10 mg/kg day every 2 weeks and TMZ 150 mg/m(2) days 1-7 and 15-21, every 28 days. Patients underwent brain magnetic resonance imaging every 8 weeks. Thirty-two evaluable pts were recruited in 8 sites. Fourteen pts (44 %) had gross total resection. O(6)-methylguanine-DNA methyltransferase (MGMT) promoter was methylated in 12 pts, unmethylated in 6 pts, and missing in 14 pts. The estimated 6-month progression free survival (PFS) rate was 21.9 % (95 % CI 9.3-40.0 %). The median PFS and overall survival (OS) were 4.2 months (95 % CI 3.6-5.4 months) and 7.3 months (95 % CI 5.8-8.8 months), respectively. No significant association with MGMT status was found in terms of OS or PFS. Six of 32 pts (19 %; 95 % CI 7.2-36.4) were long-term survivors, with a median PFS and OS (50 % events) of 9.5 months (95 % CI 7.9-23.6) and 15.4 (95 % CI 8.9-NA), respectively: no differences in baseline characteristics were identified in comparison with total population. No unexpected toxicities or treatment-related deaths were observed. This regimen showed to be feasible and well tolerated in pts with recurrent GB pretreated with TMZ. Further investigation is warranted to identify subpopulations that are more likely to benefit from addition of BV to GB therapy.
    Clinical and Translational Oncology 06/2015; 17(9). DOI:10.1007/s12094-015-1304-0
  • [Show abstract] [Hide abstract]
    ABSTRACT: The aim of this study was to estimate the effectiveness of surgery in liver metastasis from colorectal cancer. We conducted a prospective and observational study of patients with colorectal liver metastasis operated on at the San Cecilio University Hospital of Granada from March 2003 until June 2013. The primary variables of the result were survival and morbidity before 30 days of the post-operative period. We also measured preoperative and surgical variables. A total of 147 patients with liver metastasis of colorectal origin underwent surgical removal during the period of study, 38 of whom had repeat surgery. 34 had a second resection, 3 had a third one and one only patient had a fourth one, for a total of 185 registered operations. The global 5-year survival rate was 38 and 17 % after 10 years. There were 115 patients who had neither radiofrequency nor exploratory laparotomy, 38 % of them survived over 60 months. The average disease-free time was 23.6 months ± 47.3, with significant differences observed between types of procedures. Patients that were operated on just once (n = 25) had a five-year actuarial survival rate of 35 %, a morbidity rate of 24 % and a mortality rate of 0.6 % (1 patient only). The average hospital stay was 13.8 days and the disease-free time was 15.8 months. The results obtained in our surgical unit in terms of morbidity, mortality and five-year actuarial survival rates are comparable to those of other units at large institutions, which are currently considered the standards of quality.
    Clinical and Translational Oncology 03/2015; 17(7). DOI:10.1007/s12094-015-1277-z
  • L Pan · F Ren · M Rong · Y Dang · Y Luo · D Luo · G Chen
    [Show abstract] [Hide abstract]
    ABSTRACT: Researches have shown that miRNAs have been proposed as novel diagnostic biomarkers for classification and prognostic stratification of HCC. However, whether or not miR-431 contributes to the progression of HCC remains unknown. Therefore, we aimed to investigate the clinicopathological significance of miR-431 in HCC. MiR-431 expression in 95 HCC cases and corresponding adjacent non-cancerous tissues was evaluated by quantitative reverse transcription polymerase chain reaction (qRT-PCR). Furthermore, statistical analysis was performed to identify the correlations between expression of miR-431 and a variety of clinicopathological parameters and patient recurrence. The area under the receiver operating characteristic curve (AUC) was used to evaluate the accuracy of miR-431 as a biomarker for HCC diagnosis and prediction of disease deterioration. MiR-431 was markedly down-regulated in the HCC samples (1.1885 ± 0.75867) compared with corresponding adjacent tumor tissues (1.7957 ± 0.89333, P < 0.001). The AUC of low miR-431 expression to diagnose HCC was 0.668 (95 % CI 0.592-0.744, P < 0.001). MiR-431 down-expression was correlated with multiple malignant characteristics, including lymph node metastasis (r = -0.455, P < 0.001), clinical TNM stage (r = -0.223, P = 0.030), MTDH (r = -0.292, P = 0.006), vaso-invasion (r = -0.204, P = 0.047), MVD (r = -0.281, P = 0.006) and HCV (r = 0.215, P = 0.037). Additionally, the recurrent time of lower miR-431 expression group was 56.602 ± 3.914 months, much longer than that in the high expression group (50.009 ± 2.731 months), however, no significant difference was noted (χ (2) = 0.005, P = 0.943). The down-expression of miR-431 is partially responsible for a series of clinicopathological features which may be tightly correlated with the progression of HCC. Thus, expression of miR-431 may be proposed as a new factor in association with the progression of HCC.
    Clinical and Translational Oncology 03/2015; 17(7). DOI:10.1007/s12094-015-1278-y
  • [Show abstract] [Hide abstract]
    ABSTRACT: Giant cell tumor (GCT) of bone is a vessel-rich and infiltrative tumor, but the fundamental knowledge of its biological behavior remains unknown now. In this study, we evaluated the expression levels of Insulin-like growth factor 2 mRNA-binding protein 3 (IMP3), Insulin-like growth factor 2 (IGF2) and CD105 in 38 patients with GCT of spine by Immunohistochemical staining. Additionally, we also analyzed their correlations with clinicopathological factors of giant cell tumor of spine. The results showed that positive expression of IMP3 and IGF2 was tightly related to the tumor extension and local recurrence of GCT (P < 0.05), but it did not indicate any association with patients' age, gender, tumor location and size. The mean microvessel densities (MVDs) of IMP3 and IGF2 were significantly higher in positive group than negative group (P < 0.05). Moreover, a significant correlation was found between IMP3 and IGF2 expression (r = 0.355, P = 0.029). The log-rank test revealed that local recurrence-free survival time was significantly shorter in the IMP3 positive group (P = 0.004), and the difference in the IGF2 positive group and negative group was also statistically significant (P = 0.008). IMP3 and IGF2 might be potential biomarkers for GCT of spine in regulating the angiogenesis of giant cell tumor of bone and predicting the patients' prognosis.
    Clinical and Translational Oncology 03/2015; 17(7). DOI:10.1007/s12094-015-1280-4
  • [Show abstract] [Hide abstract]
    ABSTRACT: The New Year has brought a renovated editorial team to the Journal of Clinical and Translational Oncology.At the end of last year the Steering Committee of FESEO has appointed me as new Editor-in-Chief of the Journal, the successor to Dr. Andrés Cervantes and Dr. Rosario Perona to whom heartfelt thanks are due for their precious work.I am honoured to take the leadership of the Journal, which is a great challenge and a big responsibility.I have been following CTO for the last years and I can say that the Journal we have now inherited is a much better one that the one I recall many years ago.Overall, 2014 has been a successful year, papers submissions have been over 1,000 and the rejection rate worked up to 80 %. Another noteworthy feature of 2014 was the continuing improvement in publication times while maintaining high standards which lead a significant increase of citations that have continuously growing.From the pages of this Journal, I want to thank the past Editors, thanks to their ...
    Clinical and Translational Oncology 01/2015; 17(2). DOI:10.1007/s12094-015-1276-0